| 产品描述: | Dosimertinib-d5 (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d5 (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d5 (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC). |
| 体外研究: |
Dosimertinib mesylate (compound 2h) (1, 10, 100, 100 nM; 2h) 以剂量依赖性方式降低 p-EGFR 和 p-ERK 蛋白水平。 |
| 体内研究: |
Dosimertinib mesylate (0.75、1.5、3 mg/kg;口服,每天一次,持续 24 天) 在小鼠体内显示出抗肿瘤活性。 |
| 参考文献: |
1. Meng Y, et al. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. J Med Chem. 2021 Jan 28;64(2):925-937.
|
| 保存条件: |
-20°C, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.665 ml |
8.323 ml |
16.646 ml |
| 5 mM |
0.333 ml |
1.665 ml |
3.329 ml |
| 10 mM |
0.166 ml |
0.832 ml |
1.665 ml |
| 50 mM |
0.033 ml |
0.166 ml |
0.333 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |